Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing 100859, China.
World J Gastroenterol. 2023 Jun 14;29(22):3497-3507. doi: 10.3748/wjg.v29.i22.3497.
Per-oral endoscopic myotomy (POEM) is emerging as a prefer treatment option for pediatric achalasia. However, data are limited on the long-term efficacy of POEM in children and adolescents with achalasia.
To evaluate the safety and long-term efficacy of POEM for pediatric patients with achalasia and compare those outcomes with adult patients.
This retrospective cohort study was conducted in patients with achalasia who underwent POEM. Patients aged under 18 years were included in the pediatric group; patients aged between 18 to 65 years who underwent POEM in the same period were assigned to the control group. For investigation of long-term follow-up, the pediatric group were matched with patients from the control group in a 1:1 ratio. The procedure-related parameters, adverse events, clinical success, gastroesophageal reflux disease (GERD) after POEM, and quality of life (QoL) were evaluated.
From January 2012 to March 2020, POEM was performed in 1025 patients aged under 65 years old (48 in the pediatric group, 1025 in the control group). No significant differences were observed in the occurrence of POEM complications between the two groups (14.6% 14.6%; = 0.99). Among the 34 pediatric patients (70.8%) who underwent follow-up for 5.7 years (range 2.6-10.6 years), clinical success was achieved in 35 patients (35/36; 97.2%). No differences were observed in post-POEM GERD occurrence (17.6% 35.3%; = 0.10). QoL was significantly improved in both groups after POEM.
POEM is safe and effective for pediatric patients with achalasia. It can achieve significant symptoms relief and improve QoL.
经口内镜下肌切开术(POEM)作为治疗儿童贲门失弛缓症的首选治疗方法正在兴起。然而,关于 POEM 治疗儿童和青少年贲门失弛缓症的长期疗效的数据有限。
评估 POEM 治疗儿童贲门失弛缓症的安全性和长期疗效,并将这些结果与成人患者进行比较。
本回顾性队列研究纳入了接受 POEM 治疗的贲门失弛缓症患者。年龄在 18 岁以下的患者被纳入儿科组;同期接受 POEM 治疗、年龄在 18 至 65 岁之间的患者被分配到对照组。为了调查长期随访结果,将儿科组与对照组以 1:1 的比例进行匹配。评估了与手术相关的参数、不良事件、临床疗效、POEM 后胃食管反流病(GERD)和生活质量(QoL)。
2012 年 1 月至 2020 年 3 月,对 1025 名年龄在 65 岁以下的患者进行了 POEM(儿科组 48 例,对照组 1025 例)。两组患者 POEM 并发症的发生率无显著差异(14.6% 14.6%; = 0.99)。在 34 名接受了 5.7 年(2.6-10.6 年)随访的儿科患者(70.8%)中,35 名患者(35/36;97.2%)达到了临床疗效。POEM 后 GERD 的发生率无差异(17.6% 35.3%; = 0.10)。两组患者 POEM 后 QoL 均显著改善。
POEM 治疗儿童贲门失弛缓症安全有效,可显著缓解症状,改善 QoL。